(ASRNL) ASR Nederland - Ratings and Ratios
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0011872643
Insurance, Pension, Mortgage, Asset Management, Health
Description: ASRNL ASR Nederland October 31, 2025
ASR Nederland N.V. is a Dutch insurer that offers a broad suite of products-including non-life, life, pension, health, and mortgage solutions-through five operating segments: Non-Life, Life, Asset Management, Distribution & Services, and Holding & Other. Its brands (a.s.r., Aegon, Loyalis, TKP, and wijzeringeldzaken) serve individuals, entrepreneurs, and employers, covering everything from motor and travel insurance to bespoke investment funds in real-estate and renewable energy.
Recent data (2023) shows ASR’s combined ratio in the Non-Life segment at 94.5%, indicating underwriting profitability, while its total assets under management grew 6% year-over-year, driven by rising demand for sustainable real-estate assets. The Dutch insurance market is currently expanding at roughly 3% CAGR, supported by low unemployment and a regulatory push toward higher capital buffers, which could pressure earnings if interest rates remain volatile.
For a deeper quantitative view of ASR’s valuation and risk profile, the ValueRay platform offers a data-rich dashboard that can help you test your own assumptions.
ASRNL Stock Overview
| Market Cap in USD | 13,763m |
| Sub-Industry | Multi-line Insurance |
| IPO / Inception |
ASRNL Stock Ratings
| Growth Rating | 91.3% |
| Fundamental | 50.0% |
| Dividend Rating | 77.1% |
| Return 12m vs S&P 500 | 15.7% |
| Analyst Rating | - |
ASRNL Dividends
| Dividend Yield 12m | 5.58% |
| Yield on Cost 5y | 16.66% |
| Annual Growth 5y | 40.60% |
| Payout Consistency | 90.8% |
| Payout Ratio | 75.8% |
ASRNL Growth Ratios
| Growth Correlation 3m | -65.7% |
| Growth Correlation 12m | 95.9% |
| Growth Correlation 5y | 94.6% |
| CAGR 5y | 17.04% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.79 |
| CAGR/Mean DD 3y (Pain Ratio) | 3.39 |
| Sharpe Ratio 12m | 1.81 |
| Alpha | 21.41 |
| Beta | 0.688 |
| Volatility | 17.17% |
| Current Volume | 239k |
| Average Volume 20d | 345.1k |
| Stop Loss | 56.1 (-3.1%) |
| Signal | -0.24 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (1.56b TTM) > 0 and > 6% of Revenue (6% = 1.14b TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 5.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA 0.04 (>3.0%) and CFO 5.37b > Net Income 1.56b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| error: Current Ratio cannot be calculated (needs Total Current Assets and Liabilities) |
| Outstanding Shares last Quarter (206.6m) change vs 12m ago -12.31% (target <= -2.0% for YES) |
| Gross Margin 69.35% (prev 96.71%; Δ -27.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 13.06% (prev 4.89%; Δ 8.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.25 (EBITDA TTM -2.50b / Interest Expense TTM 2.74b) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 49.95
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 63.65% = 5.0 |
| 3. FCF Margin 27.95% = 6.99 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -2.41 = -2.50 |
| 6. ROIC - WACC (= -11.25)% = -12.50 |
| 7. RoE 16.73% = 1.39 |
| 8. Rev. Trend 45.32% = 3.40 |
| 9. EPS Trend -16.57% = -0.83 |
What is the price of ASRNL shares?
As of November 03, 2025, the stock is trading at EUR 57.90 with a total of 239,038 shares traded.
Over the past week, the price has changed by +0.91%, over one month by +0.21%, over three months by +1.31% and over the past year by +40.42%.
Over the past week, the price has changed by +0.91%, over one month by +0.21%, over three months by +1.31% and over the past year by +40.42%.
Is ASR Nederland a good stock to buy?
No, based on ValueRay´s Fundamental Analyses, ASR Nederland (AS:ASRNL) is currently (November 2025)
a stock to sell. It has a ValueRay Fundamental Rating of 49.95 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ASRNL is around 66.82 EUR . This means that ASRNL is currently undervalued and has a potential upside of +15.41% (Margin of Safety).
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ASRNL is around 66.82 EUR . This means that ASRNL is currently undervalued and has a potential upside of +15.41% (Margin of Safety).
Is ASRNL a buy, sell or hold?
ASR Nederland has no consensus analysts rating.
What are the forecasts/targets for the ASRNL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 61.6 | 6.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 74.5 | 28.7% |
ASRNL Fundamental Data Overview January 01, 1970
Market Cap USD = 13.76b (11.86b EUR * 1.1608 EUR.USD)
Market Cap EUR = 11.86b (11.86b EUR * 1.0 EUR.EUR)
P/E Trailing = 12.5558
P/E Forward = 9.542
P/S = 0.7245
P/B = 1.198
Beta = 0.688
Revenue TTM = 19.05b EUR
EBIT TTM = -673.5m EUR
EBITDA TTM = -2.50b EUR
Long Term Debt = 9.52b EUR (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = 6.03b EUR (from netDebt column, last quarter)
Enterprise Value = 8.37b EUR (11.86b + (null Debt) - CCE 3.49b)
Interest Coverage Ratio = -0.25 (Ebit TTM -673.5m / Interest Expense TTM 2.74b)
FCF Yield = 63.65% (FCF TTM 5.33b / Enterprise Value 8.37b)
FCF Margin = 27.95% (FCF TTM 5.33b / Revenue TTM 19.05b)
Net Margin = 8.17% (Net Income TTM 1.56b / Revenue TTM 19.05b)
Gross Margin = 69.35% ((Revenue TTM 19.05b - Cost of Revenue TTM 5.84b) / Revenue TTM)
Gross Margin QoQ = 95.47% (prev 3.89%)
Tobins Q-Ratio = 0.06 (Enterprise Value 8.37b / Total Assets 141.01b)
Interest Expense / Debt = unknown (Interest Expense 1.95b / Debt none)
Taxrate = 20.28% (188.0m / 927.0m)
NOPAT = -536.9m (EBIT -673.5m * (1 - 20.28%)) [loss with tax shield]
Current Ratio = unknown (Total Current Assets 6.28b / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -2.41 (negative EBITDA) (Net Debt 6.03b / EBITDA -2.50b)
Debt / FCF = 1.13 (Net Debt 6.03b / FCF TTM 5.33b)
Total Stockholder Equity = 9.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.10% (Net Income 1.56b / Total Assets 141.01b)
RoE = 16.73% (Net Income TTM 1.56b / Total Stockholder Equity 9.31b)
RoCE = -3.58% (EBIT -673.5m / Capital Employed (Equity 9.31b + L.T.Debt 9.52b))
RoIC = -2.70% (negative operating profit) (NOPAT -536.9m / Invested Capital 19.88b)
WACC = 8.55% (E(11.86b)/V(11.86b) * Re(8.55%) + (debt-free company))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 31.72%
[DCF Debug] Terminal Value 76.54% ; FCFE base≈5.33b ; Y1≈5.35b ; Y5≈5.73b
Fair Price DCF = 446.5 (DCF Value 92.26b / Shares Outstanding 206.6m; 5y FCF grow 0.0% → 3.0% )
EPS Correlation: -16.57 | EPS CAGR: -47.34% | SUE: 0.58 | # QB: 0
Revenue Correlation: 45.32 | Revenue CAGR: 30.79% | SUE: 3.35 | # QB: 4
Market Cap EUR = 11.86b (11.86b EUR * 1.0 EUR.EUR)
P/E Trailing = 12.5558
P/E Forward = 9.542
P/S = 0.7245
P/B = 1.198
Beta = 0.688
Revenue TTM = 19.05b EUR
EBIT TTM = -673.5m EUR
EBITDA TTM = -2.50b EUR
Long Term Debt = 9.52b EUR (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = 6.03b EUR (from netDebt column, last quarter)
Enterprise Value = 8.37b EUR (11.86b + (null Debt) - CCE 3.49b)
Interest Coverage Ratio = -0.25 (Ebit TTM -673.5m / Interest Expense TTM 2.74b)
FCF Yield = 63.65% (FCF TTM 5.33b / Enterprise Value 8.37b)
FCF Margin = 27.95% (FCF TTM 5.33b / Revenue TTM 19.05b)
Net Margin = 8.17% (Net Income TTM 1.56b / Revenue TTM 19.05b)
Gross Margin = 69.35% ((Revenue TTM 19.05b - Cost of Revenue TTM 5.84b) / Revenue TTM)
Gross Margin QoQ = 95.47% (prev 3.89%)
Tobins Q-Ratio = 0.06 (Enterprise Value 8.37b / Total Assets 141.01b)
Interest Expense / Debt = unknown (Interest Expense 1.95b / Debt none)
Taxrate = 20.28% (188.0m / 927.0m)
NOPAT = -536.9m (EBIT -673.5m * (1 - 20.28%)) [loss with tax shield]
Current Ratio = unknown (Total Current Assets 6.28b / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -2.41 (negative EBITDA) (Net Debt 6.03b / EBITDA -2.50b)
Debt / FCF = 1.13 (Net Debt 6.03b / FCF TTM 5.33b)
Total Stockholder Equity = 9.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.10% (Net Income 1.56b / Total Assets 141.01b)
RoE = 16.73% (Net Income TTM 1.56b / Total Stockholder Equity 9.31b)
RoCE = -3.58% (EBIT -673.5m / Capital Employed (Equity 9.31b + L.T.Debt 9.52b))
RoIC = -2.70% (negative operating profit) (NOPAT -536.9m / Invested Capital 19.88b)
WACC = 8.55% (E(11.86b)/V(11.86b) * Re(8.55%) + (debt-free company))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 31.72%
[DCF Debug] Terminal Value 76.54% ; FCFE base≈5.33b ; Y1≈5.35b ; Y5≈5.73b
Fair Price DCF = 446.5 (DCF Value 92.26b / Shares Outstanding 206.6m; 5y FCF grow 0.0% → 3.0% )
EPS Correlation: -16.57 | EPS CAGR: -47.34% | SUE: 0.58 | # QB: 0
Revenue Correlation: 45.32 | Revenue CAGR: 30.79% | SUE: 3.35 | # QB: 4